TechsoMed Raises $7 Million Series B financing led by Axil Capital
05 Mar, 2021
– Day One Biopharmaceuticals announced a $130m Series B financing round bringing total investment in the company to $190m.
– The round was led by RA Capital Management with participation from additional new investors Boxer Capital, BVF Partners L.P., Franklin Templeton, Janus Henderson Investors, Perceptive Advisors, funds and accounts advised by T. Rowe Price Associates, Inc., and Viking Global Investors.
– Existing investors Canaan, Access Biotechnology, and Atlas Venture also participated.
– Proceeds from the Series B financing will allow Day One to accelerate and expand its search and evaluation capabilities, support drug development efforts and continue advancing commercial launch plans for the Company’s lead program, DAY101.